Shield Therapeutics plc (LON:STX – Get Free Report) shares crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of GBX 3.03 ($0.04) and traded as low as GBX 2.70 ($0.03). Shield Therapeutics shares last traded at GBX 2.80 ($0.04), with a volume of 416,748 shares traded.
Shield Therapeutics Trading Up 1.8 %
The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The company has a 50 day moving average of GBX 3.03 and a 200 day moving average of GBX 3.14. The stock has a market capitalization of £21.90 million, a price-to-earnings ratio of -70.00 and a beta of 1.42.
Shield Therapeutics Company Profile
Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.
Further Reading
- Five stocks we like better than Shield Therapeutics
- The Risks of Owning Bonds
- Top 3 Investment Themes to Watch for in 2025
- Investing in the High PE Growth Stocks
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- What is Put Option Volume?
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.